An integrative genomics screen uncovers ncRNA T-UCR functions in neuroblastoma tumours

Oncogene

Volumn 29, Issue 24, 2010, Pages 3583-3592

  Mestdagh, P ^a   Fredlund, E ^a,b   Pattyn, F ^a   Rihani, A ^a   Van Maerken, T ^a   Vermeulen, J ^a   Kumps, C ^a   Menten, B ^a   De Preter, K ^a   Schramm, A ^c   Schulte, J ^c   Noguera, R ^d   Schleiermacher, G ^e,f   Janoueix Lerosey, I ^f   Laureys, G ^a   Powel, R ^g   Nittner, D ^h   Marine, J C ^h   Ringner M ^b   Speleman, F ^a   Vandesompele, J ^a   more..

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d UNIVERSITY OF VALENCIA   (Spain)

^e INSTITUT CURIE   (France)

^f INSTITUT CURIE   (France)

^g PrimerDesign   (United Kingdom)

^h GHENT UNIVERSITY   (Belgium)

Author keywords

Neuroblastoma; Non coding RNA; T UCR

Indexed keywords

PROTEIN P53; TRANSCRIBED ULTRACONSERVED REGION; TRANSCRIPTOME; UNCLASSIFIED DRUG; UNTRANSLATED RNA;

ARTICLE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; CONTROLLED STUDY; FUNCTIONAL GENOMICS; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; NEUROBLASTOMA; PRIORITY JOURNAL;

CELL LINE, TUMOR; CONSERVED SEQUENCE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMICS; HISTONES; HUMANS; NEUROBLASTOMA; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RNA, MESSENGER; RNA, NEOPLASM; RNA, UNTRANSLATED; TRANSCRIPTION, GENETIC;

EID: 77953808788     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.106     Document Type: Article

References (32)

1. Bartel DP. (2009). MicroRNAs: target recognition and regulatory functions. Cell 136: 215-233.
2. Bejerano G, Pheasant M, Makunin I, Stephen S, Kent WJ, Mattick JS et al. (2004). Ultraconserved elements in the human genome. Science 304: 1321-1325.
3. Bernstein BE, Kamal M, Lindblad-Toh K, Bekiranov S, Bailey DK, Huebert DJ et al. (2005). Genomic maps and comparative analysis of histone modifications in human and mouse. Cell 120: 169-181.
4. Bernstein BE, Mikkelsen TS, Xie X, Kamal M, Huebert DJ, Cuff J et al. (2006). A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125: 315-326.
5. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP et al. (1993). Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11: 1466-1477.
6. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M et al. (2009). The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 55: 611-622.
7. Calin GA, Liu CG, Ferracin M, Hyslop T, Spizzo R, Sevignani C et al. (2007). Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell 12: 215-229.
8. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT et al. (2005). Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 33: e179.
9. Corcoran DL, Pandit KV, Gordon B, Bhattacharjee A, Kaminski N, Benos PV. (2009). Features of mammalian microRNA promoters emerge from polymerase II chromatin immunoprecipitation data. PLoS One 4: e5279.
10. De Preter K, Vandesompele J, Heimann P, Yigit N, Beckman S, Schramm A et al. (2006). Human fetal neuroblast and neuroblas-toma transcriptome analysis confirms neuroblast origin and highlights neuroblastoma candidate genes. Genome Biol 7: R84.
11. Esquela-Kerscher A, Slack FJ. (2006). Oncomirs\microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269.
12. Fredlund E, Ringner M, Maris JM, Pahlman S. (2008). High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma. Proc Natl Acad Sci USA 105: 14094-14099.
13. Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D et al. (2009). Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature 458: 223-227.
14. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y et al. (2007). A microRNA component of the p53 tumour suppressor network. Nature 447: 1130-1134.
15. Khalil AM, Guttman M, Huarte M, Garber M, Raj A, Rivea Morales D et al. (2009). Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci USA 106: 11667-11672.
16. Lazcoz P, Munoz J, Nistal M, Pestana A, Encio IJ, Castresana JS. (2007). Loss of heterozygosity and microsatellite instability on chromosome arm 10q in neuroblastoma. Cancer Genet Cytogenet 174: 1-8.
17. Lefever S, Vandesompele J, Speleman F, Pattyn F. (2009). RTPri-merDB: the portal for real-time PCR primers and probes. Nucleic Acids Res 37: D942-D945.
18. Maris JM, Hogarty MD, Bagatell R, Cohn SL. (2007). Neuroblasto-ma. Lancet 369: 2106-2120.
19. Mestdagh P, Feys T, Bernard N, Guenther S, Chen C, Speleman F et al. (2008). High-throughput stem-loop RT-qPCR miRNA expression profiling using minute amounts of input RNA. Nucleic Acids Res 36: e143.
20. Mestdagh P, Van Vlierberghe P, De Weer A, Muth D, Westermann F, Speleman F et al. (2009). A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol 10: R64.
21. Mikkelsen TS, Ku M, Jaffe DB, Issac B, Lieberman E, Giannoukos G et al. (2007). Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature 448: 553-560.
22. Nobrega MA, Ovcharenko I, Afzal V, Rubin EM. (2003). Scanning human gene deserts for long-range enhancers. Science 302: 413.
23. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. (2005). c-Myc-regulated microRNAs modulate E2F1 expression. Nature 435: 839-843.
24. Pruitt KD, Tatusova T, Klimke W, Maglott DR. (2009). NCBI reference sequences: current status, policy and new initiatives. Nucleic Acids Res 37: D32-D36.
25. Rozen S, Skaletsky HJ. (2000). Primer3 on the WWW for general users and for biologist programmers. In: Krawetz S and Misener S (eds). Bioinformatics Methods and Protocols: Methods in Molecular Biology. Humana Press: Totowa, NJ. pp 365-386.
26. Schulte JH, Horn S, Otto T, Samans B, Heukamp LC, Eilers UC et al. (2008). MYCN regulates oncogenic microRNAs in neuroblastoma. Int J Cancer 122: 699-704.
27. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102: 15545-15550.
28. Van Maerken T, Speleman F, Vermeulen J, Lambertz I, De Clercq S, De Smet E et al. (2006). Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma. Cancer Res 66: 9646-9655.
29. Vandesompele J, Baudis M, De Preter K, Van Roy N, Ambros P, Bown N et al. (2005). Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma. J Clin Oncol 23: 2280-2299.
30. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z et al. (2004). in vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303: 844-848.
31. Vermeulen J, De Preter K, Naranjo A, Vercruysse L, Van Roy N, Hellemans J et al. (2009). Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol 10: 663-671.
32. Zhao S, Fernald RD. (2005). Comprehensive algorithm for quantitative real-time polymerase chain reaction. J Comput Biol 12: 1047-1064.